Makes cell-based therapies for knee cartilage repair (MACI) and severe burn treatment (Epicel, NexoBrid).
Makes cell-based therapies for knee cartilage repair (MACI) and severe burn treatment (Epicel, NexoBrid).
MACI is made per patient: surgeons send a cartilage sample, Vericel grows the person's own cells and ships them back for a second operation, and insurers pay for each case, so procedure counts drive results. Epicel is made the same way for burns; NexoBrid is licensed in from MediWound for US sales.
Moat: narrow (regulatory licence, process know-how, installed base). Complex cell-manufacturing and scarce burn-center relationships are difficult for new entrants to replicate.
Headquarters: Cambridge, Massachusetts, US · Founded: 2014 · Employees: 398
Size Vericel (VCEL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.99B, the 1544th largest of 3,085 United States companies the cockpit tracks. Shares closed at $58.65 on 18 Nov 2026.
Performance Over six months the shares gained 65.7%, against -6.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 25.3% over the last twelve months (peer median +14.8%); the operating margin is 8.3% (peer median 14.8%).
Valuation It trades at 68.3× forward earnings against a peer median of 22.1× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 46% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (10.3% WACC).
Short interest Short interest is 10.5% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $324M | $276M | $237M | $198M | $164M |
| Revenue growth | — | +16% | +20% | +20% | — |
| Gross profit | $241M | $206M | $172M | $136M | $110M |
| EBITDA | $40.6M | $22.6M | $10.0M | -$1.83M | -$8.86M |
| Net income | $33.3M | $16.5M | $10.4M | -$3.18M | -$16.7M |
| Free cash flow | $57.9M | $24.7M | -$5.81M | $15.3M | $9.02M |
| Capital expenditure | $7.42M | $27.2M | $64.0M | $27.5M | $7.60M |
| Total debt | $92.6M | $98.3M | $99.8M | $88.1M | $47.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vericel VCEL | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% |
| Organogenesis ORGO | n/a | -67% | n/a | n/a | n/a | n/a |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
| Integra LifeSciences IART | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% |
| AVITA Medical RCEL | $529M | +290% | +17% | -34% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VCEL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +44.5% | -1.4% | highest of 21 |
| 6-month return | +65.7% | -6.6% | 3rd highest of 21 |
| Distance from 52-week high | -1.8% | -29.6% | highest of 21 |
| Revenue growth (TTM) | +25.3% | +14.8% | 8th highest of 20 |
| Operating margin | 8.3% | 14.8% | 6th lowest of 19 |
| Forward P/E | 68.3× | 22.1× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 46.5% | 4.7% | most demanding of 14 |
| Growth delivered (Del g) | +17.3% | +7.0% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | +29.2 pp | -10.2 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -3.4 pp | +4.2 pp | 4th lowest of 16 |
| EV / EBITDA | 71.7× | 18.7× | most expensive of 8 |
| Net debt / EBITDA | -1.9× | -0.8× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |